PolyPid’s (PYPD) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note issued to investors on Monday,Benzinga reports. They currently have a $14.00 price target on the stock. Separately, Craig Hallum assumed coverage on shares of PolyPid in a research note on Monday, November 4th. They issued a “buy” […]
More Stories
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report issued on...
Wedbush Forecasts PepGen’s FY2028 Earnings (NASDAQ:PEPG)
PepGen Inc. (NASDAQ:PEPG – Free Report) – Equities research analysts at Wedbush raised their FY2028 earnings per share (EPS) estimates...
What is Zacks Research’s Estimate for SYF FY2026 Earnings?
Synchrony Financial (NYSE:SYF – Free Report) – Equities research analysts at Zacks Research upped their FY2026 earnings per share (EPS)...
Enterprise Products Partners (NYSE:EPD) Lowered to “Equal Weight” Rating by Wells Fargo & Company
Wells Fargo & Company lowered shares of Enterprise Products Partners (NYSE:EPD – Free Report) from an overweight rating to an...
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year Low – What’s Next?
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report)’s share price reached a new 52-week low during trading on Thursday ....
Direxion Daily Regional Banks Bull 3x Shares (NYSEARCA:DPST) Shares Gap Up – Still a Buy?
Direxion Daily Regional Banks Bull 3x Shares (NYSEARCA:DPST – Get Free Report)’s stock price gapped up before the market opened...